Jul 10, 2025 07:26AM Jones Trading Reiterates Hold Rating on Theratechnologies Inc. (THTX)

Jul 9, 2025 07:42AM Theratechnologies (THTX) Reports Q2 results

Jul 3, 2025 07:33AM Jones Trading Downgrades Theratechnologies Inc. (THTX) to Hold

Jul 2, 2025 10:47PM Theratechnologies (THTX) enters into Definitive Agreement to be Acquired by CB Biotechnology

Apr 11, 2025 09:58AM Future Pak Submits Proposals to Acquire Theratechnologies (THTX) Offering up to $255 Million in Total Value

Apr 8, 2025 07:00AM Theratechnologies (THTX) Receives FDA Approval of Prior Approval Supplement (PAS) for EGRIFTA SV sBLA

Mar 25, 2025 05:50PM Theratechnologies (THTX) announces FDA approval of EGRIFTA WR

Mar 12, 2025 07:30AM Theratechnologies (THTX) Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab

Feb 26, 2025 07:57AM Theratechnologies (THTX) Misses Q4 EPS by 16c

Dec 18, 2024 01:33PM Theratechnologies (THTX) Files FDA Prior Approval Supplement for EGRIFTA SV Manufacturing Environment

Dec 9, 2024 07:33AM Theratechnologies (THTX) Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer

Dec 4, 2024 07:30AM Theratechnologies (THTX) Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada

Dec 3, 2024 04:30PM Theratechnologies (THTX) Announces Resumed Production of EGRIFTA SV

Dec 2, 2024 07:30AM Theratechnologies (THTX) Secures up to $75M in New Credit Facilities with TD Bank and Investissement Québec

Nov 26, 2024 07:32AM Theratechnologies (THTX) Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review

Oct 17, 2024 07:31AM Theratechnologies (THTX) Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab

Sep 17, 2024 05:01PM Theratechnologies (THTX) Announces a Risk of a Temporary Supply Disruption for EGRIFTA SV in Early 2025